Yellow Sclera Syndrome – Comprehensive Medical Guide

Overview

Yellow sclera syndrome (sometimes called “jaundice of the eyes”) describes a condition in which the whites of the eyes (the sclerae) take on a yellow hue. The discoloration reflects an excess of bilirubin—a yellow pigment produced when red blood cells break down—depositing in connective tissues, including the sclera.

The syndrome is not a disease itself; rather, it is a visible sign that may accompany a range of systemic disorders, most commonly liver or hemolytic conditions. While any age group can be affected, the prevalence varies with the underlying cause. For example, in newborns, physiological jaundice (which can cause yellow sclerae) occurs in up to 60 % of full‑term infants during the first week of life [1]. In adults, yellow sclerae are observed in approximately 5 % of patients with chronic liver disease [2].

Symptoms

Yellow sclera is a clinical sign, but patients often notice accompanying symptoms that hint at the root cause. The following list groups findings by the most common underlying mechanisms.

General ocular signs

• Yellow discoloration of the sclera: A uniform, painless yellow tint that may start at the inner (nasal) side and spread outward.
• Itchy or dry eyes: May occur when underlying liver disease leads to reduced tear production.

Systemic symptoms associated with liver disease

• Fatigue, weakness, or malaise.
• Abdominal discomfort, especially in the right upper quadrant.
• Dark urine and pale stools.
• Pruritus (generalized itching), especially on the palms and soles.
• Unexplained weight loss.

Symptoms of hemolytic or blood‑related causes

• Rapid onset fatigue and shortness of breath.
• Dark urine (due to hemoglobinuria).
• Episodes of pallor or “gray” skin during hemolytic crises.
• Splenomegaly (enlarged spleen) causing left‑upper‑quadrant fullness.

Neonatal-specific signs

• Yellowing of the skin (especially on the face and trunk) within the first 2‑3 days of life.
• Feeding difficulties or lethargy in severe cases.
• High bilirubin levels on newborn screening.

Causes and Risk Factors

Yellow sclera is a symptom of elevated bilirubin. The main pathways leading to this are:

1. Hepatobiliary (liver & gallbladder) disorders

• Chronic liver disease: Cirrhosis, hepatitis B/C, alcoholic liver disease, non‑alcoholic fatty liver disease (NAFLD).
• Biliary obstruction: Gallstones, cholangiocarcinoma, primary sclerosing cholangitis.
• Acute liver injury: Drug‑induced hepatitis (e.g., acetaminophen overdose), viral hepatitis.

2. Hemolytic conditions

• Hereditary spherocytosis, G6PD deficiency, sickle cell disease.
• Autoimmune hemolytic anemia, transfusion reactions.

3. Neonatal physiological jaundice

• Immature liver enzyme systems (especially UDP‑glucuronosyltransferase).
• Breast‑feeding jaundice or breast‑milk jaundice.

4. Inherited metabolic disorders

• Gilbert syndrome (mild, intermittent hyperbilirubinemia).
• Crigler‑Najjar syndrome (severe deficiency of bilirubin‑conjugating enzymes).

Risk factors

• Heavy alcohol use, obesity, and diabetes (increase NAFLD risk).
• Chronic viral hepatitis infection.
• Family history of hemolytic anemia or metabolic bilirubin disorders.
• Premature birth or low birth weight (higher neonatal jaundice risk).
• Use of certain medications (e.g., isoniazid, rifampin, some antibiotics) that impair bilirubin metabolism.

Diagnosis

Diagnosing yellow sclera syndrome begins with confirming the presence of scleral discoloration and then identifying the underlying cause of hyperbilirubinemia.

Clinical evaluation

• Detailed medical history (liver disease, medications, family history, newborn feeding).
• Physical examination focusing on the abdomen, skin, and lymphatic system.

Laboratory tests

1. Serum bilirubin panel – total, direct (conjugated) and indirect (unconjugated) bilirubin.
2. Liver function tests (LFTs) – ALT, AST, alkaline phosphatase, GGT, albumin, PT/INR.
3. Complete blood count (CBC) with reticulocyte count – evaluates hemolysis.
4. Hemolysis work‑up – haptoglobin, LDH, peripheral smear.
5. Viral hepatitis serologies – Hepatitis B surface antigen, Hepatitis C antibody.
6. Genetic testing – when hereditary disorders (e.g., Gilbert, G6PD) are suspected.

Imaging studies

• Abdominal ultrasound – assesses liver texture, gallbladder stones, bile duct dilation.
• Magnetic resonance cholangiopancreatography (MRCP) – detailed view of biliary tree in complex cases.
• Transient elastography (FibroScan) – non‑invasive measurement of liver fibrosis.

Special tests

• Phototherapy response in neonates – helps differentiate physiologic from pathological jaundice.
• Liver biopsy – rarely needed, but may be performed when imaging is inconclusive.

Treatment Options

Therapy targets the underlying cause rather than the yellow sclera itself. Management is individualized based on the diagnosis.

1. Liver‑related interventions

• Lifestyle modification – weight loss, alcohol cessation, low‑saturated‑fat diet (AASLD recommends ≥5 % weight loss to improve NAFLD) [3].
• Pharmacologic therapy
  • Antivirals for chronic hepatitis B (e.g., tenofovir) or C (direct‑acting antivirals).
  • Ursodeoxycholic acid for primary biliary cholangitis.
  • Obeticholic acid for certain cholestatic diseases.
• Procedural options
  • Endoscopic retrograde cholangiopancreatography (ERCP) to relieve biliary obstruction.
  • Liver transplantation for end‑stage cirrhosis or acute liver failure.

2. Hemolysis‑directed treatment

• Stop offending drugs or treat infections precipitating hemolysis.
• Folic acid supplementation (1 mg daily) to support erythropoiesis.
• Blood transfusions in severe anemia.
• Immunosuppressive therapy (e.g., corticosteroids, rituximab) for autoimmune hemolytic anemia.
• Splenectomy in refractory hereditary spherocytosis.

3. Neonatal care

• Phototherapy – blue‑light wavelengths (420–470 nm) convert bilirubin to water‑soluble forms.
• Exchange transfusion – reserved for bilirubin >20 mg/dL or signs of bilirubin‑induced neurologic dysfunction.
• Breast‑feeding support and adequate hydration to promote bilirubin excretion.

4. Symptomatic relief

• Lubricating eye drops for dryness.
• Vitamin K (if coagulopathy is present) to reduce bleeding risk.

Living with Yellow Sclera Syndrome

Even after the underlying disease is managed, patients may experience ongoing visual or quality‑of‑life concerns. Below are practical tips.

Daily management

• Monitor bilirubin levels as advised by your physician—typically every 3‑6 months for chronic liver disease.
• Maintain a food diary to identify foods that may worsen liver function (e.g., high‑fructose drinks).
• Stay well‑hydrated – at least 2 L of water daily unless restricted for heart/kidney disease.
• Use protective eyewear in bright sunlight to reduce ocular discomfort.
• Schedule regular eye examinations (yearly) to assess scleral color and rule out secondary eye disease.

Emotional support

• Join support groups for chronic liver disease or hemolytic anemia (e.g., American Liver Foundation, Sickle Cell Disease Association).
• Consider counseling if anxiety about appearance or disease progression becomes overwhelming.

When to adjust treatment

• New or worsening abdominal pain, swelling, or confusion.
• Rapid increase in scleral yellowing despite therapy.
• Any sign of bleeding (easy bruising, dark stools, hematuria).

Prevention

Because yellow sclera is a marker of another disease, prevention focuses on reducing the risk of those primary conditions.

• Vaccinate against hepatitis A and B.
• Limit alcohol intake to ≤14 g per day for women and ≤28 g for men (CDC guideline).
• Maintain a healthy weight (BMI < 25) to lower NAFLD risk.
• Practice safe medication use—avoid over‑the‑counter drugs that interfere with bilirubin metabolism without physician guidance.
• For newborns, ensure early feeding (within the first hour of life) to reduce physiologic jaundice.

Complications

If the underlying cause of hyperbilirubinemia remains uncontrolled, several serious complications may arise.

• Progressive liver failure – leading to ascites, hepatic encephalopathy, and coagulopathy.
• Portal hypertension – variceal bleeding risk.
• Hepatocellular carcinoma – incidence increases with cirrhosis (≈1–4 % per year) [4].
• Kernicterus – irreversible neurologic damage in neonates with bilirubin >20 mg/dL.
• Chronic anemia – fatigue, organ hypoxia.
• Psychosocial impact – body image concerns and reduced quality of life.

When to Seek Emergency Care

Prompt evaluation can prevent irreversible organ damage and improve outcomes.

---

References

1. Mayo Clinic. “Neonatal jaundice.” Updated 2023. https://www.mayoclinic.org
2. Cleveland Clinic. “Jaundice and Yellow Sclera.” 2022. https://my.clevelandclinic.org
3. American Association for the Study of Liver Diseases (AASLD). “Guidelines for NAFLD management.” 2023.
4. World Health Organization. “Hepatocellular carcinoma.” Global Cancer Facts & Figures 2022.
5. Centers for Disease Control and Prevention. “Hepatitis B vaccination.” 2024. https://www.cdc.gov